Gane E, de Ledinghen V, Dylla DE, Rizzardini G, et al. Positive predictive value of sustained virologic response 4 weeks posttreatment for achieving sustained virologic response 12 weeks posttreatment in patients receiving glecaprevir/pibrentasvir in Phase 2 and 3 clinical trials. J Viral Hepat 2021;28:1635-1642.
PMID: 34448313